Zdrowie i gospodarka · 02/03/2012
FDA Drafts Guidance on Phthalate Use in Regulated Products
The FDA has released a draft guidance advising the pharmaceutical industry to limit the use of certain phthalates, including DBP and DEHP, as excipients in CDER-regulated products to mitigate potential human health risks.
Source: Federal Register — Food and Drug AdministrationOpen original release →